🚀 Hims Appoints Former Lilly Executive to Lead Communications
#Hims #KathrynBeiser #Lilly #telehealth #obesitymedications #communications #healthcare
Hims has announced the appointment of Kathryn Beiser as its new communications leader. Bloomberg posted on X, highlighting Beiser's previous experience at Lilly, where she managed communications for five years. This strategic move comes as Hims embarks on a new phase, focusing on the sale of brand-name obesity medications. The telehealth company aims to leverage Beiser's expertise to enhance its communication strategies and expand its market presence in the healthcare sector.#Hims #KathrynBeiser #Lilly #telehealth #obesitymedications #communications #healthcare
🚀 U.S. Supreme Court Allows Racketeering Lawsuit Against Takeda and Lilly Over Actos
#USSupremeCourt #RacketeeringLawsuit #Takeda #Lilly #Actos #BladderCancer #DiabetesDrug #DeceptivePractices #LegalBattle #PharmaceuticalLawsuit #ConsumerSafety
The U.S. Supreme Court has permitted a multibillion-dollar racketeering lawsuit to proceed against pharmaceutical companies Takeda and Lilly. Bloomberg posted on X, highlighting that the lawsuit accuses the companies of marketing the diabetes drug Actos without revealing its potential link to bladder cancer. This decision marks a significant development in the legal battle surrounding Actos, which has been the subject of numerous lawsuits over its safety. The plaintiffs allege that Takeda and Lilly engaged in deceptive practices by failing to disclose the risks associated with the drug, leading to widespread harm among consumers. The case will now move forward in the legal system, potentially resulting in substantial financial repercussions for the companies involved.#USSupremeCourt #RacketeeringLawsuit #Takeda #Lilly #Actos #BladderCancer #DiabetesDrug #DeceptivePractices #LegalBattle #PharmaceuticalLawsuit #ConsumerSafety